Allspring Global Investments’s Dianthus Therapeutics DNTH Stock Holding History

Allspring Global Investments’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Buy	+4,642	New	+$405K	﹤0.01%	1491

Other funds holding DNTH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Allspring Global Investments's DNTH Position: Q2 2026 in Review

Allspring Global Investments opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 4,642 shares worth $419K. The stake represents ﹤0.01% of the portfolio and ranks #1491 among its holdings.

204 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Allspring Global Investments held 4,642 shares of Dianthus Therapeutics worth $419K as of Q2 2026.
Dianthus Therapeutics was a new Allspring Global Investments position in Q2 2026.
Dianthus Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1491 holding.
204 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.